Tesamorelin: Molecular Structure

Molecular Structure and Properties#

Tesamorelin is a synthetic 44-amino acid peptide analog of human growth hormone-releasing hormone (GHRH(1-44)NH2) with a molecular weight of 5135.9 Da and the molecular formula C221H366N72O67S1. It is distinguished from native GHRH by the covalent attachment of a trans-3-hexenoic acid moiety to the alpha-amino group of the N-terminal tyrosine residue. The CAS registry number for tesamorelin is 218949-48-5.

Amino Acid Sequence#

The primary structure of tesamorelin is identical to that of human GHRH(1-44)NH2, with the sole modification being the N-terminal acylation. The complete sequence is:

(Trans-3-hexenoic acid)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2

The C-terminus is amidated (Leu-NH2), which is consistent with the native GHRH(1-44) sequence and is important for biological activity. The peptide contains a single methionine residue at position 27, which is susceptible to oxidation and represents a potential degradation pathway during storage.

Trans-3-Hexenoic Acid Modification#

The trans-3-hexenoic acid modification is the defining structural feature that distinguishes tesamorelin from native GHRH and from other GHRH analogs such as sermorelin. This six-carbon unsaturated fatty acid is conjugated to the N-terminal tyrosine residue through an amide bond, forming an N-acylated derivative.

Purpose and Rationale#

The primary purpose of the hexenoic acid modification is to protect the peptide from rapid enzymatic degradation by dipeptidyl peptidase-IV (DPP-IV). Native GHRH is rapidly inactivated in the circulation by DPP-IV, which cleaves the Tyr1-Ala2 peptide bond at the N-terminus, generating the inactive metabolite GHRH(3-44)NH2. This cleavage is the rate-limiting step in GHRH degradation and accounts for the extremely short half-life of native GHRH (approximately 5-8 minutes in human plasma).

The trans-3-hexenoic acid moiety provides steric protection to the Tyr1-Ala2 bond by creating a bulky hydrophobic group adjacent to the DPP-IV cleavage site. This conformational shielding significantly reduces the rate of DPP-IV-mediated proteolysis without abolishing GHRH receptor binding, as the key receptor-binding determinants of GHRH reside primarily in the N-terminal 29 amino acids with particular importance placed on residues 1-12.

Structural Consequences#

The hexenoic acid modification introduces a small lipophilic element that may influence the following physicochemical properties:

• Increased hydrophobicity at the N-terminus, potentially affecting peptide folding and aggregation behavior in solution
• Slight increase in overall molecular weight (approximately 96 Da contribution from the hexenoic acid)
• Retention of the alpha-helical secondary structure in the N-terminal region that is critical for GHRH receptor engagement
• No significant alteration of the receptor-binding pharmacophore, as demonstrated by preserved binding affinity and full agonist activity at the GHRH receptor

Stability and Formulation#

Tesamorelin is manufactured as a sterile, white to off-white lyophilized powder for subcutaneous injection. The commercial formulation (Egrifta/Egrifta SV) contains tesamorelin acetate along with mannitol as a bulking agent and is supplied as single-use vials.

Reconstitution and Physical Properties#

The lyophilized powder is reconstituted with sterile water for injection prior to administration. The original Egrifta formulation required reconstitution with a larger diluent volume, while the reformulated Egrifta SV (approved 2020) uses a smaller reconstitution volume for improved ease of use and reduced injection volume.

Upon reconstitution, the solution should be clear and colorless. The peptide is soluble in aqueous media at physiological pH. The reconstituted solution should be used immediately or stored under refrigerated conditions for a limited period.

Storage Conditions#

• Lyophilized powder: Store at controlled room temperature 20-25 degrees C (68-77 degrees F), with excursions permitted between 15-30 degrees C (59-86 degrees F)
• Reconstituted solution: Use immediately; if not used immediately, refrigerate at 2-8 degrees C (36-46 degrees F) and use within the manufacturer's recommended timeframe
• Protect from light and moisture

Degradation Pathways#

The primary degradation pathways for tesamorelin include:

• Oxidation of the methionine residue at position 27 to methionine sulfoxide
• Deamidation of asparagine and glutamine residues
• Hydrolysis of peptide bonds, particularly at elevated temperatures or extreme pH
• Potential aggregation in concentrated solutions

The trans-3-hexenoic acid modification itself is chemically stable under normal storage conditions and does not represent a significant degradation liability.

Pharmacokinetics#

Tesamorelin pharmacokinetics have been characterized in clinical studies following subcutaneous administration, the approved route of delivery.

Absorption#

Following subcutaneous injection of the 2 mg approved dose in HIV-infected patients with lipodystrophy, tesamorelin is absorbed with a median time to peak concentration (Tmax) of approximately 0.15 hours (approximately 9-10 minutes), though published estimates range from approximately 10 to 20 minutes depending on the study population and analytical methodology. Peak plasma concentrations are achieved rapidly, consistent with the relatively small molecular size of the peptide and the subcutaneous depot characteristics.

Distribution#

Tesamorelin distributes into the systemic circulation following subcutaneous absorption. Detailed volume of distribution data from human studies have not been extensively published. As a peptide hormone analog, it is expected to distribute primarily in the extracellular fluid compartment with limited tissue penetration beyond vascularized organs.

Metabolism and Elimination#

Tesamorelin is metabolized primarily through proteolytic degradation, as is typical for peptide therapeutics. The terminal elimination half-life following subcutaneous administration is approximately 26 minutes, though some estimates report values in the range of 26-38 minutes. This relatively short half-life is consistent with ongoing, albeit reduced, proteolytic degradation despite the protective hexenoic acid modification.

The short half-life raises the question of how once-daily dosing achieves sustained pharmacological effects. The answer lies in the downstream pharmacodynamics: tesamorelin triggers GH release in discrete pulses, and the resulting GH and IGF-1 elevations persist well beyond the plasma presence of tesamorelin itself. Thus, the pharmacological effect is decoupled from the plasma half-life of the parent peptide.

Comparison to Native GHRH#

Compared to native GHRH(1-44)NH2, which has a plasma half-life of only 5-8 minutes due to rapid DPP-IV cleavage, tesamorelin demonstrates an approximately 3-5 fold improvement in circulating half-life. While still short in absolute terms, this improvement is sufficient to allow once-daily subcutaneous dosing to produce clinically meaningful and sustained GH stimulation, as validated by the Phase 3 clinical trial outcomes demonstrating significant visceral fat reduction over 26-52 weeks of treatment.

Receptor Binding and Functional Activity#

Tesamorelin acts as a full agonist at the GHRH receptor (GHRHR), a class B G-protein coupled receptor expressed on anterior pituitary somatotroph cells. The binding interaction triggers Gs-protein-mediated activation of adenylate cyclase, elevation of intracellular cAMP, and activation of protein kinase A, ultimately driving transcription and secretion of growth hormone.

The trans-3-hexenoic acid modification does not significantly impair receptor binding affinity or intrinsic activity. In vitro and in vivo studies demonstrate that tesamorelin retains full agonist efficacy at the GHRHR, with potency comparable to native GHRH when assessed by GH release in clinical studies. The preserved biological activity combined with enhanced metabolic stability represents the core pharmacological advantage of the hexenoic acid modification strategy.

Related Reading#

• Tesamorelin overview and research guide
• Peptides similar to Tesamorelin
• Tesamorelin research evidence